Syndax Pharmaceuticals. has been granted a patent for methods to select cancer patients for combination therapy using an HDAC inhibitor and an anti-PD-1 antibody. The method involves analyzing specific immune cell markers in a blood sample to determine eligibility for treatment. GlobalData’s report on Syndax Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Syndax Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Syndax Pharmaceuticals's grant share as of June 2024 was 19%. Grant share is based on the ratio of number of grants to total number of patents.
Patient selection for hdac inhibitor combination cancer therapy
The granted patent US12000829B2 outlines a method for selecting patients for combination therapy involving entinostat and an anti-PD-1 antibody, specifically targeting those diagnosed with cancer. The method involves obtaining a peripheral blood sample from the patient and measuring the presence of specific immune cell markers: CD14-positive, HLA-DR-high, and CD16-negative cells. The therapy is administered if these cells constitute a percentage greater than a predetermined threshold, which can range from at least 5% to as high as 50% of the total peripheral blood mononuclear cells. The method is particularly relevant for patients who have previously shown progression on anti-PD-1 or related therapies and may have been considered unresponsive to such treatments.
Additionally, the patent specifies that the peripheral blood sample may be treated with anticoagulants like EDTA or heparin, and outlines various administration protocols for entinostat, including oral dosing on a weekly or bi-weekly basis. The anti-PD-1 antibody, which may include pembrolizumab, can be administered by infusion. The method is applicable to various cancer types, including non-small cell lung cancer, melanoma, breast cancer, and ovarian cancer, with specific subtypes mentioned. The claims also allow for the sequential or simultaneous administration of entinostat and the anti-PD-1 antibody, providing flexibility in treatment approaches for eligible patients.
To know more about GlobalData’s detailed insights on Syndax Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
